Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) recently announced that executive management will participate in the UBS Global Life Sciences Conference to be held September 21 - 23, 2009 at the Grand Hyatt in New York City. Mr. Armando Anido, Chief Executive Officer and President, is scheduled to present an overview of Auxilium Pharmaceuticals and its product pipeline.
Wall Street Grand is a leading online financial publication. We are pleased to alert investors of stocks that are on the move.
Sign Up for our Free Stock Newsletter
The presentation is scheduled for 10:30 a.m. EDT on Monday, September 21, 2009. To listen to the audio web cast of the presentation during or after the event, please visit our web site. The replay will be available for ninety days after the event. Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company with a focus on developing and marketing to urologists, endocrinologists, orthopedists and select primary care physicians. Auxilium markets Testim® 1%, a topical testosterone gel, for the treatment of hypogonadism through its approximately 190-person sales and marketing team. Auxilium has five projects in clinical development. XIAFLEX™ (collagenase clostridium histolyticum), formerly referred to as AA4500, has completed phase III clinical trials for the treatment of Dupuytren's disease, and the biologics license application is under review at the FDA for the treatment of Dupuytren's disease. XIAFLEX is in phase IIb of development for the treatment of Peyronie's disease and is in phase II of development for treatment of Frozen Shoulder syndrome (Adhesive Capsulitis). Auxilium's transmucosal film product candidate for the treatment of overactive bladder (AA4010) and its fentanyl pain product using its transmucosal delivery system are in phase I of development. The Company is currently seeking a partner to further develop these product candidates. Auxilium has rights to additional pain products and products for hormone replacement and urologic disease using its transmucosal film delivery system. Auxilium also has options to all indications using XIAFLEX for non-topical formulations.
Sign up for Today for our free Wall Street Grand newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.
About Wall Street Grand
Wall Street Grand is the best investor relations company on the web. From Research Reports to Stock Profiles, we give you everything you need to make the best investment decisions daily. Each of our Featured Investment Opportunities hold premium characteristics to succeed even our own expectations making us the best kept secret of Wall Street.
To feature a company on our web site please contact us at the email listed below.
Wall Street Grand's stock profiles are intended to be stock ideas, NOT recommendations. Please do your own research before investing. Please click here to read the full disclaimer.
